Professor Zhaoyan Jiang, who supervised the study, emphasized the significance of this liver-sparing approach. “One of the ...

Rivus Pharmaceuticals has released data showing the muscle-sparing benefit of its weight loss drug in a Phase IIa in obese patients with heart failure with preserved ejection fraction (HFpEF).